Faecalibacterium prausnitzii induces an anti-inflammatory response and a metabolic reprogramming in human monocytes
Authors:
- Camille DanneCDCamille Danne
- Laura CreusotLCLaura Creusot
- Rodrigo de Oliveira FormigaRFRodrigo de Oliveira Formiga
- Florian MarquetFMFlorian Marquet
- Delphine SeddaDSDelphine Sedda
- Laura HuaLHLaura Hua
- Pauline RuffiéPRPauline Ruffié
- Hang-Phuong PhamHPHang-Phuong Pham
- Iria Alonso SalgueiroISIria Alonso Salgueiro
- Loic BrotLBLoic Brot
- Marie-Laure MichelMMMarie-Laure Michel
- Philippe LangellaPLPhilippe Langella
Preprint
Abstract
Background and aims: Faecalibacterium prausnitzii , a highly abundant bacterium in the human gut microbiota, has been linked to overall health and is decreased in several pathological conditions, such as Inflammatory Bowel Disease (IBD). F. prausnitzii has shown anti-inflammatory properties in human and mouse models, notably through the induction of IL-10 signaling. Here, we investigated which cell types from human blood and intestinal tissue are responsible for producing IL-10 induced by F. prausnitzii , and providing the first mechanistic insights. Methods: Immune cells isolated from human blood and intestinal lamina propria of patients with IBD and non-inflamed controls, were stimulated with either F. prausnitzii EXL01 strain or Escherichia coli lipopolysaccharide (LPS) and analysed by Legendplex, ELISA, flow cytometry, RNA-sequencing (RNAseq), and Seahorse technology. Results: F. prausnitzii EXL01 strain induced the direct and dose-dependent production of IL-10 in CD14 + monocytes from the systemic circulation and intestinal tissue of IBD patients and non-inflamed controls, without inducing a pro-inflammatory response as compared to LPS stimulation. RNAseq analysis corroborated these results and revealed that F. prausnitzii EXL01 strain differentially affects cell energy metabolism compared to LPS. The anti-inflammatory response induced by F. prausnitzii in monocytes was dependent on mitochondrial respiration. Conclusion: F. prausnitzii induces an anti-inflammatory response and rewires energy metabolism in human monocytes, which might explain its beneficial impact on intestinal inflammation and human health in general. These results provide new insight into the mechanisms underlying the anti-inflammatory effects of F. prausnitzii and are crucial for a better understanding of its potential use in the treatment of IBD.Keywords
This publication has 53 references indexed in Scilit:
- Immune cell metabolism and metabolic reprogrammingMolecular Biology Reports, 2022
- The Gut Microbiota at the Service of ImmunometabolismCell Metabolism, 2020
- Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in MiceImmunity, 2019
- Gut microbiota in the pathogenesis of inflammatory bowel diseaseClinical Journal of Gastroenterology, 2017
- Macrophage Immunometabolism: Where Are We (Going)?Trends in Immunology, 2017
- The Treatment-Naive Microbiome in New-Onset Crohn’s DiseaseCell Host & Microbe, 2014
- Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitisJournal of Crohn's and Colitis, 2013
- Faecalibacterium prausnitzii and human intestinal healthCurrent Opinion in Microbiology, 2013
- Genetics and pathogenesis of inflammatory bowel diseaseNature, 2011
- Comparative proteomic studies on the pathogenesis of human ulcerative colitisProteomics, 2006